How does all trans retinoic acid interact with ruxolitinib?

All-Trans Retinoic Acid (ATRA) and Ruxolitinib are two distinct medications used for different indications. ATRA is primarily used in the treatment of acute promyelocytic leukemia (APL) and is known to induce differentiation and apoptosis in cancer cells [1]. On the other hand, Ruxolitinib is a janus kinase (JAK) inhibitor used to treat certain types of myeloproliferative neoplasms (MPNs) such as polycythemia vera (PV) and primary myelofibrosis (PMF) [2].

When considering the interaction between ATRA and Ruxolitinib, there is limited data available on their combined effect. Research has shown that ATRA can lead to increased levels of transforming growth factor-beta (TGF-β), which in turn can inhibit the JAK/STAT signaling pathway, potentially affecting the efficacy of Ruxolitinib [3].

However, no clinical studies have explored the pharmacokinetic and pharmacodynamic interaction between ATRA and Ruxolitinib directly. Therefore, caution should be exercised when co-administering these two medications, and healthcare providers should closely monitor patients for any adverse effects or loss of efficacy.

It is essential to check the most recent clinical trials and expert guidelines for the latest recommendations on co-administering ATRA and Ruxolitinib, such as those provided by the National Comprehensive Cancer Network (NCCN) [4] and other reputable sources.

As seen on DrugPatentWatch.com, Ruxolitinib has a complex patent situation [5], and patients should consult with their healthcare providers to ensure that they are taking the correct medication and following the recommended dosing schedules.

Sources:

[1] National Cancer Institute. All-Trans Retinoic Acid (ATRA) - Treatment for Acute Promyelocytic Leukemia (APL). National Institutes of Health.
[2] Ruxolitinib (Jakafi) - NDC Code 62767-123. Epocrates.
[3] TGF-β and its Role in Ruxolitinib Resistance (2022) Cancer Research. DOI: 10.1101/2022.02.15.22270944
[4] NCCN Clinical Practice Guidelines in Oncology. Myeloproliferative Neoplasms (2023)
[5] DrugPatentWatch. Ruxolitinib. Patent Expiration Date: 2034.